Novartis AG Settles Off-Label Marketing Case Over 6 Drugs for $422.5 Million

New York Times -- The Swiss drug giant Novartis is paying $422.5 million to settle criminal and civil investigations into the marketing of the antiseizure medicine Trileptal and five other drugs, federal officials said on Thursday.